Helena Tayton-Martin
Oprichter bij ADAPTIMMUNE THERAPEUTICS PLC
Vermogen: 318 060 $ op 30-04-2024
Actieve functies van Helena Tayton-Martin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 15-03-2017 | - |
Oprichter | 01-01-2008 | - | |
Operationeel Directeur | 01-01-2008 | 15-03-2017 | |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Directeur/Bestuurslid | - | - |
Operationeel Directeur | 17-09-2009 | - | |
Oprichter | 01-01-2008 | - | |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | President | - | - |
Bedrijfssecretaris | - | - |
Loopbaan van Helena Tayton-Martin
Eerdere bekende functies van Helena Tayton-Martin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TRILLIUM THERAPEUTICS | Directeur/Bestuurslid | 01-10-2017 | 17-11-2021 |
Independent Dir/Board Member | 01-10-2017 | 17-11-2021 | |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Operationeel Directeur | 01-01-2008 | 01-01-2017 |
Oprichter | 01-01-2008 | 01-01-2017 | |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Opleiding van Helena Tayton-Martin
London Business School | Masters Business Admin |
University of Bristol | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 6 |
Verenigde Staten | 3 |
Canada | 2 |
Operationeel
Chief Operating Officer | 3 |
Founder | 3 |
Director/Board Member | 2 |
Sectoraal
Health Technology | 5 |
Health Services | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |